Saturday 21 December 2024
Internal Reference Number: FOI_8035
Date Request Received: 08/07/2024 00:00:00
Date Request Replied To: 15/07/2024 00:00:00
This response was sent via: By Email
Request Summary: Diffuse Large B Cell Lymphoma (DLBCL)
Request Category: Private Individuals
| Question Number 1: In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? 1a. Of these patients, how many commenced treatment at your trust within the last 6 months? | |
| Answer To Question 1: 1. 7 patients have been diagnosed with Diffuse Large B Cell Lymphoma. 1a. 6 of the 7 patients diagnosed were treated within the last six months. | |
| Question Number 2: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) Pola-BR (polatuzumab vedotin with rituximab and bendamustine) Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) Axicabtagene ciloleucel (Yescarta) Tisagenlecleucel Epcoritamab Loncastuximab tesirine Glofitamab Any other SACT Stem cell transplant or bone marrow transplant (autologous or allogeneic) | |
| Answer To Question 2: -CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) <5 patients. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) <5 patients Pola-BR (polatuzumab vedotin with rituximab and bendamustine) <5 patients Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) 6 patients R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) 0 patients R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) 0 patients Axicabtagene ciloleucel (Yescarta) 0 patients Tisagenlecleucel 0 patients Epcoritamab <5 patients Loncastuximab tesirine 0 patients Glofitamab 0 patients Any other SACT <5 patients Stem cell transplant or bone marrow transplant (autologous or allogeneic) - These are referred to UHS - please contact Southampton for information if required: freedomofinformation@uhs.nhs.uk | |
| Question Number 3: In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL): Axicabtagene ciloleucel (Yescarta) Tisagenlecleucel Pola-BR (polatuzumab vedotin with rituximab and bendamustine) Stem cell transplant or bone marrow transplant (autologous or allogeneic) Any other treatments | |
| Answer To Question 3: Axicabtagene ciloleucel (Yescarta) Tisagenlecleucel 0 patients Pola-BR (polatuzumab vedotin with rituximab and bendamustine) <5 patients Stem cell transplant or bone marrow transplant (autologous or allogeneic) Not currently being done on site. 0 patients. These are referred to UHS - please contact Southampton for information if required: freedomofinformation@uhs.nhs.uk Any other treatments <5 | |
| Question Number 4: In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments: CAR-T Therapy (E.g. Axicabtagene ciloleucel) Stem cell transplant or bone marrow transplant (autologous or allogeneic) Any other treatment | |
| Answer To Question 4: CAR-T Therapy (E.g. Axicabtagene ciloleucel) <5 Stem cell transplant or bone marrow transplant (autologous or allogeneic) These are referred to UHS - please contact Southampton for information if required: freedomofinformation@uhs.nhs.uk Any other treatment - CNS DLBCL <5 patients | |
| Question Number 5: Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling? | |
| Answer To Question 5: No active DLBCL trials at present | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
